CytomX Therapeutics, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2021-02-26

Reporting Person: McCarthy Sean A. (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-26	Stock Option (right to buy)	$7.85	A	400000	Acquired	2031-02-25	Common Stock (400000)	Direct
2021-02-27	Stock Option (Right to Buy)	$7.85	A	200000	Acquired	2031-02-26	Common Stock (200000)	Direct

Footnotes

F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.